For the quarter ending 2025-09-30, NDRA had -$1,014,537 decrease in cash & cash equivalents over the period. -$1,164,003 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,858,201 | - |
| Depreciation and amortization | 33,928 | - |
| Stock compensation expense | 144,722 | 171,809 |
| Changes in fair value of warrant liability | - | 470,674 |
| Net loss | - | -2,262,242 |
| Amortization of right of use assets | 28,603 | 55,231 |
| (increase) decrease in prepaid expenses | 210,361 | -159,873 |
| (increase) decrease in accounts payable and accrued liabilities | 223,095 | -59,871 |
| Decrease in lease liability | -32,163 | -24,112 |
| Changes in fair value of warrant liability | -203,400 | - |
| Fixed assets write off | 0 | - |
| Inventory reserve | 0 | - |
| Depreciation and amortization | - | 23,142 |
| Warrant expense | 0 | - |
| Fixed assets write off | - | 0 |
| Gain or loss on settlement of warrant exercise | 0 | - |
| Inventory reserve | - | 0 |
| Increase in inventory | 0 | 0 |
| Net cash used in operating activities | -1,164,003 | -2,406,844 |
| Proceeds from sale of fixed assets | - | 0 |
| Purchases of fixed assets | 0 | 17,280 |
| Proceeds from sale of fixed assets | 0 | - |
| Net cash used in investing activities | 0 | -17,280 |
| Repayment of loan | - | 0 |
| Proceeds from issuance of common stock | 149,466 | 1,003,218 |
| Proceeds from warrant issuances and exercises | 0 | 0 |
| Repayment of loan | 0 | - |
| Net cash provided by financing activities | 149,466 | 1,003,218 |
| Net increase (decrease) in cash | -1,014,537 | -1,420,906 |
| Cash and cash equivalents at beginning of period | 3,229,480 | - |
| Cash and cash equivalents at end of period | 794,036 | - |
ENDRA Life Sciences Inc. (NDRA)
ENDRA Life Sciences Inc. (NDRA)